Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution

World Journal of Cardiology, Journal Year: 2025, Volume and Issue: 17(2)

Published: Feb. 24, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) has exceeded HF reduced (HFrEF), becoming the most common type of HF. Unlike HFrEF, HFpEF is primarily a chronic low-grade inflammatory process closely associated metabolic disorders. The coexistence and dysfunction-associated steatotic liver disease (MASLD) presents significant clinical challenges due to shared pathophysiology complex interplay. Management strategies for MASLD remain challenging. Sodium-glucose cotransporter 2 inhibitors have shown benefits in managing both conditions. Additionally, glucagon-like peptide-1 receptor agonists are being actively investigated their potential benefits, particularly MASLD. A comprehensive, patient-centered approach that combines cardiovascular care essential improving outcomes patients MASLD, addressing global health challenges.

Language: Английский

Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy

Journal of Clinical Personalized Medicine, Journal Year: 2025, Volume and Issue: 04(02), P. 826 - 834

Published: Jan. 1, 2025

Language: Английский